載入...
Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials
BACKGROUND: Despite advances with new therapies, a significant proportion of patients (>30%) suffer delayed-onset chemotherapy-induced nausea and vomiting (CINV) despite use of antiemetics. APF530 is a sustained-release subcutaneous (SC) formulation of granisetron for preventing CINV. APF530 phar...
Na minha lista:
發表在: | Cancer Manag Res |
---|---|
Main Authors: | , , , , , , |
格式: | Artigo |
語言: | Inglês |
出版: |
Dove Medical Press
2015
|
主題: | |
在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4370683/ https://ncbi.nlm.nih.gov/pubmed/25834466 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S72626 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|